Homepage Top Section2

Based in Mumbai, IQGEN-X provides niche and complex drug development technologies for the pharmaceutical industry. IQGENX was founded in October 2016 to provide advanced research and technology for

The deal has a total enterprise value of around $368m. Based in Cambridge, Horizon Discovery offers CRISPR and RNAi reagents, cell models, cell engineering and base editing solutions

Under the deal, Cheplapharm will purchase Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide), which is marketed in around 70 countries across

Under the deal, Bristol Myers Squibb and insitro will focus on the discovery and development of novel therapies to treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

The US government will take the delivery of bamlanivimab vials after it achieves an emergency use authorisation (EUA) from the US Food and Drug Administration (FDA), said Eli

Gavi is the legal administrator of the COVAX Facility, which is part of COVAX, a global collaboration of governments, global health organisations, businesses and philanthropic organisations working to

As per terms of the deal, Asklepios will secure an upfront consideration of $2bn and potential success-based milestone payments of up to $2bn from Bayer. Based in North

The orphan drug status to iptacopan has been granted by the regulator after a recommendation from the Committee for Orphan Medicinal Products (COMP). Although considered to be a

NantKwest and ImmunityBio’s hAd5-Covid-19 is a novel Covid-19 vaccine candidate designed to target the inner nucleocapsid (N) and the outer spike (S) protein, as well as activate both